Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511254 | 1.00 | PYGM (0.41) | PYGMTK1P2RY6P2RY14TSHR | |
| SCHEMBL13976552 | 0.89 | PYGM (0.46) | PYGMTK1P2RY6P2RY14TSHR | |
| SCHEMBL16307200 | 0.89 | PYGM (0.46) | PYGMTK1P2RY6P2RY14TSHR | |
| SCHEMBL13976532 | 0.89 | PYGM (0.46) | PYGMTK1P2RY6P2RY14TSHR | |
| SCHEMBL14702170 | 0.87 | ALDH1A1 (0.42) | TK1LMNA | |
| SCHEMBL14929163 | 0.87 | ALDH1A1 (0.42) | TK1LMNA | |
| SCHEMBL14946289 | 0.87 | ALDH1A1 (0.42) | TK1LMNA | |
| SCHEMBL14702179 | 0.84 | TK1 (0.32) | TK1TSHRLMNAMAPTPMP22 | |
| SCHEMBL14511253 | 0.84 | TK1 (0.32) | TK1TSHRLMNAMAPTPMP22 | |
| SCHEMBL13976629 | 0.81 | PYGM (0.36) | PYGMTK1P2RY6P2RY14BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779118-B2 | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130041011-A1 | BASE MODIFIED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041011-A1 | BASE MODIFIED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NSUN2 | PYGM 972/4885TK1 383/4885P2RY6 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.